| Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials Early Breast Cancer Trialists' Collaborative Group The Lancet 386 (10001), 1341-1352, 2015 | 1277 | 2015 |
| aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. RG Gray, D Rea, K Handley, SJ Bowden, P Perry, HM Earl, CJ Poole, ... Journal of Clinical Oncology 31 (18_suppl), 5-5, 2013 | 651 | 2013 |
| Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors A O'Donnell, S Faivre, HA Burris III, D Rea, V Papadimitrakopoulou, ... Journal of Clinical Oncology 26 (10), 1588-1595, 2008 | 561 | 2008 |
| Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial CJH Van de Velde, D Rea, C Seynaeve, H Putter, A Hasenburg, ... The Lancet 377 (9762), 321-331, 2011 | 478 | 2011 |
| Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas M Cullen, N Steven, L Billingham, C Gaunt, M Hastings, P Simmonds, ... New England Journal of Medicine 353 (10), 988-998, 2005 | 470 | 2005 |
| Addressing overtreatment of screen detected DCIS; the LORIS trial A Francis, J Thomas, L Fallowfield, M Wallis, JMS Bartlett, C Brookes, ... European journal of cancer 51 (16), 2296-2303, 2015 | 352 | 2015 |
| Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer LW Seymour, DR Ferry, DJ Kerr, D Rea, M Whitlock, R Poyner, C Boivin, ... International journal of oncology 34 (6), 1629-1636, 2009 | 337 | 2009 |
| Reviews of evidence regarding interventions to reduce tobacco use and exposure to environmental tobacco smoke DP Hopkins, PA Briss, CJ Ricard, CG Husten, VG Carande-Kulis, ... American journal of preventive medicine 20 (2), 16-66, 2001 | 335 | 2001 |
| Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer … R Gray, R Bradley, J Braybrooke, Z Liu, R Peto, L Davies, D Dodwell, ... The lancet 393 (10179), 1440-1452, 2019 | 314 | 2019 |
| 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial HM Earl, L Hiller, AL Vallier, S Loi, K McAdam, L Hughes-Davies, ... The Lancet 393 (10191), 2599-2612, 2019 | 293 | 2019 |
| Ductal carcinoma in situ: to treat or not to treat, that is the question M van Seijen, EH Lips, AM Thompson, S Nik-Zainal, A Futreal, ES Hwang, ... British journal of cancer 121 (4), 285-292, 2019 | 279 | 2019 |
| Association between age at diagnosis and disease-specific mortality among postmenopausal women with hormone receptor–positive breast cancer W van de Water, C Markopoulos, CJH van de Velde, C Seynaeve, ... Jama 307 (6), 590-597, 2012 | 259 | 2012 |
| Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer SA Hussain, R Ganesan, G Reynolds, L Gross, A Stevens, J Pastorek, ... British journal of cancer 96 (1), 104-109, 2007 | 255 | 2007 |
| Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer CJ Poole, HM Earl, L Hiller, JA Dunn, S Bathers, RJ Grieve, DA Spooner, ... New England Journal of Medicine 355 (18), 1851-1862, 2006 | 235 | 2006 |
| Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane … JMS Bartlett, CL Brookes, T Robson, CJH van de Velde, LJ Billingham, ... Journal of clinical oncology 29 (12), 1531, 2011 | 234 | 2011 |
| Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial NC Turner, B Kingston, LS Kilburn, S Kernaghan, AM Wardley, ... The Lancet Oncology 21 (10), 1296-1308, 2020 | 232 | 2020 |
| Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor α induction in vivo PA Philip, D Rea, P Thavasu, J Carmichael, NSA Stuart, H Rockett, ... JNCI: Journal of the National Cancer Institute 85 (22), 1812-1818, 1993 | 216 | 1993 |
| Comparing breast cancer multiparameter tests in the OPTIMA prelim trial: no test is more equal than the others JMS Bartlett, J Bayani, A Marshall, JA Dunn, A Campbell, C Cunningham, ... JNCI: Journal of the National Cancer Institute 108 (9), djw050, 2016 | 214 | 2016 |
| Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly (ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers … Y Drew, J Ledermann, G Hall, D Rea, R Glasspool, M Highley, G Jayson, ... British journal of cancer 114 (7), 723-730, 2016 | 192 | 2016 |
| Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials R Bradley, J Braybrooke, R Gray, R Hills, Z Liu, R Peto, L Davies, ... The Lancet Oncology 22 (8), 1139-1150, 2021 | 184 | 2021 |
